-
Product Insights
New![]()
Net Present Value Model: Cerevel Therapeutics Holdings Inc’s Darigabat
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Cerevel Therapeutics Holdings Inc’s Tavapadon
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Cerevel Therapeutics Holdings Inc’s Emraclidine
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Cerevel Therapeutics Holdings Inc's Emraclidine Drug Details: Emraclidine (CVL-231) is under development for the treatment of schizophrenia experiencing an acute exacerbation of psychosis and...
-
Product Insights
New![]()
Net Present Value Model: Cerevel Therapeutics Holdings Inc’s CVL-871
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: VBI Vaccines Inc’s VBI-1901
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Entera Bio Ltd’s EB-613
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVL-562 in Schizophrenia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CVL-562 in Schizophrenia Drug Details: CVL-562 (PF-06412562) is under development for the treatment of Schizophrenia. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVL-871 in Dementia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVL-871 in Dementia Drug Details: CVL-871 is under development for the treatment of dementia related...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVL-354 in Opium (Opioid) Addiction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CVL-354 in Opium (Opioid) AddictionDrug Details:CVL-354 is under development for the treatment of opioid use disorder...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LY-3549492 in Type 2 Diabetes
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3549492 in Type 2 Diabetes Drug Details: LY-3549492 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVL-354 in Major Depressive Disorder
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CVL-354 in Major Depressive DisorderDrug Details:CVL-354 is under development for the treatment of opioid use disorder...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVL-936 in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CVL-936 in Substance (Drug) AbuseDrug Details:CVL-936 is under development for the treatment of substance use disorder....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Fibromyalgia (Fibromyalgia Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Naltrexone Hydrochloride in Fibromyalgia (Fibromyalgia Syndrome)Drug Details:ARD-301 is under development for the treatment of fibromyalgia (fibromyalgia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Darigabat in Panic Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Darigabat in Panic Disorders Drug Details: Darigabat (CVL-865) is under development for the treatment of ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Emraclidine in Schizophrenia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emraclidine in Schizophrenia Drug Details: Emraclidine (CVL-231) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Emraclidine in Psychosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emraclidine in Psychosis Drug Details: Emraclidine (CVL-231) is under development for the treatment of schizophrenia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ITI-1284 in Psychosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ITI-1284 in Psychosis Drug Details:Deuterated lumateperone (ITI- 1284) is under development for the treatment of behavioural...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RP-12146 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RP-12146 in Pancreatic Cancer Drug Details:RP-12146 is under development for the treatment of solid tumors (BRCA...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AL-8326 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AL-8326 in Solid Tumor Drug Details:AL-8326 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer Drug Details: Ifinatamab deruxtecan (DS-7300) is under...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.